Related Experiment Video
Updated: Apr 13, 2026
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
2.0K
Targeting the microenvironment in acute myeloid leukemia
1Section of BMT & Leukemia, Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave. Campus Box 8007, St. Louis, MO, 63110, USA.
Current Hematologic Malignancy Reports
|April 30, 2015
Summary
Targeting the bone marrow microenvironment can combat acute myeloid leukemia (AML) progression and relapse. AML cells interact with their surroundings, leading to chemotherapy resistance, a key area for new therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- The bone marrow microenvironment is crucial for acute myeloid leukemia (AML) development, progression, and relapse.
- AML blasts, like normal stem cells, interact with the microenvironment via surface receptors.
- These interactions contribute to chemotherapy resistance and disease recurrence.
Purpose of the Study:
- To explore the role of the bone marrow microenvironment in AML.
- To investigate targeting tumor-microenvironment interactions for AML therapy.
- To identify potential therapeutic agents for AML.
Main Methods:
- Review of preclinical studies and early phase clinical trials.
- Identification of key molecular targets within the tumor-microenvironment axis.
- Analysis of agents under investigation for AML treatment.
Main Results:
- Tumor-microenvironment interactions are a viable therapeutic target in AML.
- Several agents show promise in preclinical and early clinical settings.
- Targeting CXCR4, VLA-4, and E-selectin are strategies being explored.
Conclusions:
- Targeting the bone marrow microenvironment offers a promising strategy for overcoming AML chemoresistance and relapse.
- Further investigation and clinical trials of agents targeting these interactions are warranted.
- Novel therapeutic approaches focusing on the AML niche are essential for improving patient outcomes.
Related Concept Videos
02:17The Tumor Microenvironment
8.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
02:17The Tumor Microenvironment
3.2K
3.2K
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K